120-Day Expedited Reviews: “Up-Front” Planning Is Key, FDA/Industry Says
This article was originally published in The Gray Sheet
Executive Summary
Coordination of advisory panel meetings will be key to implementing 120-day expedited reviews for breakthrough devices, FDA and AdvaMed agree